Skip To Main Content
Changying Li on Muck Rack

Changying Li

Albany
As seen in: Nature, Wiley Online Library, MDPI, Taylor & Francis Online, BMC Genomics, Dove Medical Press, Dialnet - Universidad de La Rioja, Optica, Resource Magazine, Cancer Treatment Reviews and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Changying

Contact Changying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Supply chain competition and the welfare effects of partial ownership

|
By Changying Li, YUE LI, Larry Qiu
| Wiley Online Library Verified
DATA AVAILABILITY STATEMENT No data is used in this study.
Open in Who Shared Issue with article?

Author Correction: Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC

|
By Xin Xu, Xin McRae Chen, Rongli Xu, Zhenyu Huo, Changying Li, Somaira Nowsheen, Khaled Aziz, Fan Yao, Zhenkun Lou, Min Deng
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-026-69695-4, published online 24 February 2026 In the version of the article initially published, in Fig. 1c, in the “AsPC-1” panel, the “Vehicle, DAPI” column was inadvertently duplicated from the “MRTX1133, DAPI” column. The figure has now been corrected using the appropriate DAPI images. This correction has been made to the HTML and PDF versions of the article.
Open in Who Shared Issue with article?

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC - Nature Communications

|
By Xin Xu, Xin McRae Chen, Rongli Xu, Zhenyu Huo, Changying Li, Somaira Nowsheen, Khaled Aziz, Fan Yao, Zhenkun Lou, Min Deng
| Nature Verified
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy driven predominantly by KRAS mutations, with KRASG12D present in ~40 % of cases. Although the selective KRASG12D inhibitor MRTX1133 shows promising activity, monotherapy responses are incomplete and resistance emerges rapidly.
Open in Who Shared Issue with article?
See all 22 licensed articles (24 Total)